The 10 most recent market catalysts affecting $COR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330
RBC Capital's initiation of coverage on Cencora (COR) with a 'Sector Perform' rating and a $330 price target provides a new data point for investors. While 'Sector Perform' is a ne…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 75
Cencora shares are trading lower after the company announced that certain Walgreens volume moved outside its business beginning July 1, 2026.
This news is a significant corporate catalyst for Cencora (COR) as it signals a future reduction in revenue and market share due to the loss of a portion of Walgreens' business. Wh…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 65
Cencora Says Certain Walgreens Volume Moves Outside Cencora From July 1, 2026; Reaffirms FY26 Adj Diluted EPS Guidance Range Of $17.75-$17.95; Says Prime Vendor Agreement With Walgreens Remains Unchanged
Cencora disclosed that 'certain Walgreens volume' will no longer be serviced by them starting July 1, 2026. This volume is distinct from the 'prime vendor agreement,' which remains…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Cencora, Raises Price Target to $395
Wells Fargo analyst Stephen Baxter maintained an 'Overweight' rating on Cencora and significantly raised the price target from $331 to $395. This action signals a strong vote of co…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Cencora, Raises Price Target to $390
This filing discloses that JP Morgan has maintained its 'Overweight' rating on Cencora and raised its price target from $382 to $390. This action by a major investment bank signals…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Cencora, Raises Price Target to $430
UBS analyst Kevin Caliendo maintained a 'Buy' rating on Cencora (COR) and raised the price target from $412 to $430. This action signals continued bullish sentiment from a major in…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Cencora, Raises Price Target to $350
Evercore ISI Group's analyst John Belton has raised the price target for Cencora (COR) from $330 to $350 while maintaining an 'Outperform' rating. This action signals increased con…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora's Q3 results exceeded analyst expectations for both earnings and sales, primarily due to robust demand in specialty products and the strategic acquisition of OneOncology. T…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Cencora shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance with its midpoint above estimates.
This headline represents a major corporate catalyst for Cencora, indicating strong fundamental performance and a positive future outlook. The better-than-expected Q2 results and, m…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Cencora Q3 Adj. EPS $4.48 Beats $4.35 Estimate, Sales $84.754B Beat $84.315B Estimate
Cencora's Q3 earnings report shows a significant beat on both adjusted EPS and sales estimates. The adjusted EPS of $4.48 surpassed the $4.35 consensus by 2.99% and represented a 1…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.